E07.0 ICD-10-CM Code: Hypersecretion of calcitonin
E07.0 is not a CMS-HCC payment code. MEAT criteria · RAF Calculator · free HCC coding tools
HCC Buddy Code Card
Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.
FY 2026 Apr update / Endocrine, nutritional and metabolic diseases (E00-E89) / Disorders of thyroid gland (E00-E07)
E07.0
Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidanceHypersecretion of calcitonin
Excessive production of calcitonin, a hormone that regulates calcium levels, which can indicate medullary thyroid cancer or other endocrine disorders.
Buddy Insight
Hypersecretion of calcitonin indicates excessive production of calcitonin, most commonly associated with medullary thyroid carcinoma (MTC), C-cell hyperplasia, or rarely as a paraneoplastic phenomenon.
CMS-HCC V28
N/A—
Not mapped
CMS-HCC V24
HistoricalHistorical
Not used for CY2026 payment
ACA/HHS
N/A—
Not mapped
ESRD/PACE
N/A—
Not mapped
RXHCC
MappedHCC 44
Code-level coefficient reference
Code Book Path
Inclusion Terms
Official- C-cell hyperplasia of thyroid
- Hypersecretion of thyrocalcitonin
Excludes 2
OfficialNo Excludes 2 notes are included in this display for E07.0. Check the code and parent instructions in the Code Book.
Related Codes
Includes
OfficialNo Includes notes are included in this display for E07.0. Check the code and parent instructions in the Code Book.
Excludes 1
Official- transitory endocrine and metabolic disorders specific to newborn (P70-P74)Inherited from E00-E89
Code First
OfficialNo Code First sequencing instructions are included in this display for E07.0. Check the code and parent instructions in the Code Book.
Use Additional
OfficialNo Use Additional Code instructions are included in this display for E07.0. Check the code and parent instructions in the Code Book.
Code Also
OfficialNo Code Also instructions are included in this display for E07.0. Check the code and parent instructions in the Code Book.
Buddy Documentation Tip
MEAT Support
Audit Caution
Current with CMS: FY2026 ICD-10-CM Apr 1 update (effective Apr 1 – Sep 30, 2026) · CMS-HCC V28, 100% phased in for payment year 2026. FY2027 code set already staged for October 1, 2026. How HCC Buddy stays current →
Is E07.0 an HCC code?
E07.0 has no mapping under the current CMS-HCC V28 community payment model. E07.0 has a separate mapping under the Part D RxHCC model (HCC 44 (Thyroid Disorders)); the applicable result needs member context.
- Code
- E07.0
- Description
- Hypersecretion of calcitonin
- HCC (V28)
- No CMS-HCC V28 mapping
- RAF reference coefficient
- —
- Billable
- Yes
- Payment year
- 2026
HCC Category Mapping
These are source-labeled model coefficients, not member totals. A category may still be removed by hierarchy or model cleanup rules. Weights are not directly comparable across models: CMS-HCC V28 and V24 use Community, Non-Dual, Aged; ESRD uses the dialysis continuing-enrollee model; RxHCC is the Part D continuing-enrollee, non-low-income, aged weight (a larger scale than CMS-HCC). ACA/HHS has no single weight — it varies by metal level. Actual per-patient RAF contribution depends on member context, hierarchy and cleanup rules, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains available for historical review.
Work E07.0 in the Code Book — tabular path, V28 RAF reference, and MEAT checklist →
MEAT review for E07.0
For E07.0, confirm that the documentation supports the diagnosis and meets the applicable coding, encounter, program and payer requirements. MEAT (Monitor, Evaluate, Assess, or Treat) is a review mnemonic, not a universal CMS coding rule.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Coder workflow notes
Get the V28 mapping + MEAT cheat sheet
One printable reference: check representative V28 mappings and the documentation reminders your note needs. Free, no card.
Free PDF. No card. Unsubscribe anytime.
What This Code Means
E07.0 is the ICD-10-CM diagnosis code for hypersecretion of calcitonin. Excessive production of calcitonin, a hormone that regulates calcium levels, which can indicate medullary thyroid cancer or other endocrine disorders. E07.0 sits in the ICD-10-CM chapter for endocrine, nutritional and metabolic diseases (e00-e89), within the section covering disorders of thyroid gland (e00-e07).
E07.0 has no mapping under the current CMS-HCC V28 community payment model. E07.0 has a separate mapping under the Part D RxHCC model (HCC 44 (Thyroid Disorders)); the applicable result needs member context. Do not assign V28 risk adjustment value from this page; verify the applicable model and payment year before using this code for risk adjustment.
Elevated calcitonin levels warrant investigation for medullary thyroid carcinoma.
HCC Buddy maintains structured V28 and V24 mapping, source-labeled coefficient references, and MEAT documentation criteria for E07.0 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Elevated calcitonin levels warrant investigation for medullary thyroid carcinoma
- •Document baseline and stimulated calcitonin levels when available
Clinical Significance
Hypersecretion of calcitonin indicates excessive production of calcitonin, most commonly associated with medullary thyroid carcinoma (MTC), C-cell hyperplasia, or rarely as a paraneoplastic phenomenon. Elevated calcitonin serves as both a diagnostic marker and tumor surveillance tool for MTC, with levels correlating to tumor burden. This condition warrants thorough evaluation to exclude malignancy, particularly in patients with family history of MEN2 syndromes.
Documentation Requirements
- ✓Document the serum calcitonin level, the underlying cause of hypersecretion (medullary thyroid carcinoma, C-cell hyperplasia, or other), imaging findings, and whether genetic testing for RET proto-oncogene mutations has been performed.
- ✓If MTC is confirmed, a separate malignancy code should be assigned as the primary diagnosis.